Novotech

Novotech is a leading global clinical research organization (CRO) specializing in biotechnology-focused clinical development, providing comprehensive clinical trial services for pharmaceutical, biotechnology, and healthcare companies. Founded in 1996 and headquartered in Adelaide, Australia, Novotech supports emerging and established biotech organizations in advancing innovative therapies from early development through regulatory approval.

The company provides full-service clinical research solutions including Phase I–IV clinical trials, clinical operations, regulatory affairs, patient recruitment, clinical data management, biostatistics, medical writing, pharmacovigilance, and laboratory services.

Novotech has strong expertise in biotechnology-driven therapeutic areas including oncology, immunology, cell and gene therapies, rare diseases, infectious diseases, and advanced biologics. The company works closely with biotech sponsors to design efficient clinical development programs and navigate complex regulatory environments.

With a global network of clinical trial sites, investigators, and research professionals across Asia-Pacific, North America, and Europe, Novotech helps sponsors conduct international clinical studies while maintaining high standards of quality and compliance.

The company combines scientific expertise with technology-enabled clinical research solutions to improve trial efficiency, patient recruitment, and data management. Novotech is particularly recognized for supporting biotechnology companies seeking specialized expertise in accelerating innovative treatments toward market approval.

Novotech follows international clinical research standards including Good Clinical Practice (GCP), ICH guidelines, FDA regulations, EMA requirements, and global quality systems.

With more than 25 years of experience, Novotech has become a trusted clinical development partner for biotech innovators worldwide, helping transform promising scientific discoveries into approved healthcare solutions.